抗TIF1-γ抗体、抗核抗体ANA及抗GAD65抗体等多重抗体阳性的成人皮肌炎一例并文献回顾
A Case of Adult Dermatomyositis with Multiple Positive Antibodies, Including Anti-TIF1-γ Antibodies, Anti-Nuclear Antibodies (ANA), and Anti-GAD65 Antibodies, and Literature Review
DOI: 10.12677/ACM.2024.141273, PDF,   
作者: 刘 梦, 唐光情, 孙晓瑞, 邸 伟*:西安医学院研工部,陕西 西安
关键词: 皮肌炎自身抗体Dermatomyositis Autoantibodies
摘要: 皮肌炎(dermatomyositis, DM)是一种由自身免疫介导的主要累及皮肤和肌肉,也可能损伤心、肺、肾及消化道等多个系统的弥漫性骨骼肌炎症性结缔组织病,少数患者合并其他自身免疫病,如类风湿性关节炎、系统性红斑狼疮及进行性系统性硬化等。典型临床表现为对称性四肢近端肌肉无力、肌肉疼痛、眶周和上下眼睑水肿性淡紫色斑和Gottron征。遗传、感染、免疫及肿瘤等均可能参与发病。多数患者血清或脑脊液可检测到一种类型自身抗体,而多种自身抗体重叠较罕见。本研究分析了2023年3月1日就诊于陕西省人民医院神经内一科的1例多重自身抗体阳性的皮肌炎,并结合文献从发病机制、临床表现、辅助检查及治疗等方面进行讨论。本次研究经过本院医学伦理委员会同意。
Abstract: Dermatomyositis (DM) is a diffuse skeletal muscle inflammatory connective tissue disease primarily affecting the skin and muscles, which can also damage multiple systems such as the heart, lungs, kidneys, and digestive tract. A minority of patients may also develop other autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and progressive systemic sclerosis. Typical clinical manifestations include symmetrical weakness of the proximal muscles of the limbs, muscle pain, periorbital and eyelid edema with a dusky violet color, and Gottron’s sign. Genetic fac-tors, infections, immune dysregulation, and tumors may all contribute to the development of the disease. Most patients can be detected with a specific type of autoantibody in their serum or cere-brospinal fluid, although the overlap of multiple autoantibodies is rare. This study analyzed a case of dermatomyositis with multiple positive autoantibodies, which was treated at the Department of Neurology, Shaanxi Provincial People’s Hospital on March 1, 2023, and conducted a discussion on the pathogenesis, clinical manifestations, auxiliary examinations, and treatment based on existing literature. This study was approved by the Medical Ethics Committee of our hospital.
文章引用:刘梦, 唐光情, 孙晓瑞, 邸伟. 抗TIF1-γ抗体、抗核抗体ANA及抗GAD65抗体等多重抗体阳性的成人皮肌炎一例并文献回顾[J]. 临床医学进展, 2024, 14(1): 1936-1942. https://doi.org/10.12677/ACM.2024.141273

参考文献

[1] Tanboon, J. and Nishino, I. (2022) Update on Dermatomyositis. Current Opinion in Neurology, 35, 611-621. [Google Scholar] [CrossRef
[2] Constante, M., Barradas, A., Esteves, A., Pereira, S. and Silva, L. (2022) Dermatomyositis: A Cancer Red Flag. Cureus, 14, e32502. [Google Scholar] [CrossRef] [PubMed]
[3] 李筱筱, 李雨薇, 孙莉, 等. 特发性炎性肌病不同亚型临床特征、肌炎抗体谱、肌电图的差异性表现[J]. 疑难病杂志, 2023, 22(5) :515-519.
[4] D’Silva, K., Li, L., Lu, N., Ogdie, A., Avina-Zubieta, J. and Choi, H. (2021) Persistent Premature Mortality Gap in Dermatomyositis and Polymyositis: A United Kingdom General Population-Based Cohort Study. Rheumatology, 60, 2653-2660. [Google Scholar] [CrossRef] [PubMed]
[5] Osaki, M., Tachikawa, R., Ohira, J., Hara, S. and Tomii, K. (2021) Anti-Transcriptional Intermediary Factor 1-γ Antibody-Positive Dermatomyositis Induced by Nivolumab for Lung Adenocarcinoma: A Case Report. Investigational New Drugs, 39, 251-255. [Google Scholar] [CrossRef] [PubMed]
[6] 谭艳平, 刘志刚. 皮肌炎/多发性肌炎病因及发病机制的研究进展[J]. 中国皮肤性病学杂志, 2016, 30(6): 634-636, 649.
[7] DeWane, M., Waldman, R. and Lu, J. (2020) Der-matomyositis: Clinical Features and Pathogenesis. Journal of the American Academy of Dermatology, 82, 267-281. [Google Scholar] [CrossRef] [PubMed]
[8] Megremis, S., Walker, T., He, X., O’Sullivan, J., Ollier, W., Chi-noy, H., et al. (2021) Analysis of Human Total Antibody Repertoires in TIF1γ Autoantibody Positive Dermatomyositis. Communications Biology, 4, Article No. 419. [Google Scholar] [CrossRef] [PubMed]
[9] 周娅丽, 胥璟, 杨静, 等. 皮肌炎107例患者肌电图与临床特征的回顾性分析[J]. 临床皮肤科杂志, 2022, 51(11): 644-647. [Google Scholar] [CrossRef
[10] Kim, N., Nam, E., Kang, J., Song, H., Im, C. and Kang, Y. (2014) Complex Repetitive Discharge on Electromyography as a Risk Factor for Malignancy in Idiopathic In-flammatory Myopathy. The Korean Journal of Internal Medicine, 29, 814-821. [Google Scholar] [CrossRef] [PubMed]
[11] Spalkit, S., Sinha, A., Prakash, M. and Sandhu, M. (2021) Der-matomyositis: Patterns of MRI Findings in Muscles, Fascia and Skin of Pelvis and Thigh. European Journal of Radiol-ogy, 141, Article ID: 109812. [Google Scholar] [CrossRef] [PubMed]
[12] Ashton, C., Paramalingam, S., Stevenson, B., Brusch, A. and Needham, M. (2021) Idiopathic Inflammatory Myopathies: A Review. Internal Medicine Journal, 51, 845-852. [Google Scholar] [CrossRef] [PubMed]
[13] Chua, C., Low, J., Lim, W. and Manghani, M. (2022) Characteristics of Anti-Transcriptional Intermediary Factor 1 γ Autoantibody-Positive Dermatomyositis Patients in Singapore. Annals of the Academy of Medicine of Singapore, 51, 755-765. [Google Scholar] [CrossRef] [PubMed]
[14] Dani, L., Holmqvist, M., MartÍNez, M., Tral-lero-Araguas, E., Dastmalchi, M., Svensson, J., et al. (2020) Anti-Transcriptional Intermediary Factor 1 γ Antibodies in Cancer-Associated Myositis: A Longitudinal Study. Clinical and Experimental Rheumatology, 38, 67-73.
[15] Solimena, M., Folli, F., Denis-Donini, S., Comi, G., Pozza, G., De, Camilli, P., et al. (1988) Autoantibodies to Glutamic Acid De-carboxylase in a Patient with Stiff-Man Syndrome, Epilepsy, and Type I Diabetes Mellitus. The New England Journal of Medicine, 318, 1012-1020. [Google Scholar] [CrossRef
[16] Baizabal-Carvallo, J. (2019) The Neurological Syndromes Associated with Glutamic Acid Decarboxylase Antibodies. Journal of Autoimmun-ity, 101, 35-47. [Google Scholar] [CrossRef] [PubMed]
[17] Dade, M., Berzero, G., Izquierdo, C., Giry, M., Benazra, M., Delattre, J., et al. (2020) Neurological Syndromes Associated with Anti-GAD Antibodies. International Journal of Molecular Sciences, 21, Article 3701. [Google Scholar] [CrossRef] [PubMed]
[18] Daif, A., Lukas, R., Issa, N., Javed, A., VanHaerents, S., Reder, A., et al. (2018) Antiglutamic Acid Decarboxylase 65 (GAD65) Antibody-Associated Epilepsy. Epilepsy and Behavior, 80, 331-336. [Google Scholar] [CrossRef] [PubMed]
[19] Hoesly, P., Sluzevich, J., Jambusaria-Pahlajani, A., Lesser, E., Heckman, M. and Abril, A. (2019) Association of Antinuclear Antibody Status with Clinical Features and Malignancy Risk in Adult-Onset Dermatomyositis. Journal of the American Academy of Dermatology, 80, 1364-1370. [Google Scholar] [CrossRef] [PubMed]
[20] Ceribelli, A., Isailovic, N., De, Santis, M., Generali, E., Fredi, M., Cavazzana, I., et al. (2017) Myositis-Specific Autoantibodies and Their Association with Malignancy in Italian Patients with Polymyositis and Dermatomyositis. Clinical Rheumatology, 36, 469-475. [Google Scholar] [CrossRef] [PubMed]
[21] 高颖, 黄瑶, 侯彦波, 等. 抗谷氨酸脱羧酶65抗体阳性相关中枢神经系统病变临床特点分析[J]. 中风与神经疾病杂志, 2022, 39(7) : 647-649. [Google Scholar] [CrossRef
[22] 邱占东, 刘峥, 李大伟, 等. 多重抗神经元抗体阳性的神经系统副肿瘤综合征临床分析[J]. 中国神经免疫学和神经病学杂志, 2020, 27(4) : 261-265. [Google Scholar] [CrossRef
[23] 田春艳, 谷涛, 陈桂生. 多重抗体神经系统副肿瘤综合征临床特征分析[J]. 宁夏医学杂志, 2023, 45(1): 19-21. [Google Scholar] [CrossRef
[24] Zhen, C., Hou, Y., Zhao, B., Ma, X., Dai, T. and Yan, C. (2022) Efficacy and Safety of Rituximab Treatment in Patients with Idiopathic Inflammatory Myopathies: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 13, Article 1051609. [Google Scholar] [CrossRef] [PubMed]
[25] Cobos, G., Femia, A. and Vleugels, R. (2020) Dermatomyositis: An Update on Diagnosis and Treatment. American Journal of Clinical Dermatology, 21, 339-353. [Google Scholar] [CrossRef] [PubMed]
[26] Pipitone, N. and Salvarani, C. (2020) Up-To-Date Treatment and Management of Myositis. Current Opinion in Rheumatology, 32, 523-527. [Google Scholar] [CrossRef
[27] Smith, L. and Paik, J. (2020) Promising and Upcoming Treatments in Myositis. Current Rheumatology Reports, 22, Article No. 65. [Google Scholar] [CrossRef] [PubMed]